Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Recombinant antibodies for the detection and neutralization of anthrax toxin

a technology of neutralizing antibodies and anthrax, which is applied in the field of antibody engineering, can solve the problems of antibodies not having the affinity and avidity required for widespread use, and the method of prophylaxis treatment of patients exposed to bacillus anthracis /i>cannot achieve the effect of reducing the risk of infection

Active Publication Date: 2008-10-23
BOARD OF RGT THE UNIV OF TEXAS SYST
View PDF5 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0011]It has been found, however, that present compositions and methods for the prophylatic treatment of patients exposed to Bacillus anthracis fail to target the protective antigen or toxin of the bacterium in a man...

Problems solved by technology

It has been found, however, that present compositions and methods for the prophylatic treatment of patients exposed to Bacillus anthracis fail to target the protective antigen or toxin of the bacterium in a manner that allows antibiotic treatment to have a full effect on infectious disease.
A significant problem of current treatment regimes is that the antibodies fail to have the required affinity and avidity for widespread use.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Recombinant antibodies for the detection and neutralization of anthrax toxin
  • Recombinant antibodies for the detection and neutralization of anthrax toxin
  • Recombinant antibodies for the detection and neutralization of anthrax toxin

Examples

Experimental program
Comparison scheme
Effect test

examples

[0056]Cloning from Hybridomas. The heavy and light variable chain regions are cloned from anti-PA hybridoma 14B7 via RT-PCR (Krebber A, Bornhauser S, Burmester J, Honegger A, Willuda J, et al. 1997. Reliable cloning of functional antibody variable domains from hybridomas and spleen cell repertoires employing a reengineered phage display system. J Immunol Methods 201: 35-55). VH and VL genes are joined by overlap PCR and cloned into pAK100 phage display vector using 5 prime and 3 prime SfiI sites. Single colonies in E. coli strain are grown in a 96-well plate, and phage displaying scFv are produced and screened by ELISA to identify PA-reactive clones.

[0057]Antibody Affinity Maturation. Error-prone libraries of the 14B7 scFv gene are constructed using manganese and biased nucleotide ratios (Daugherty P, Chen G, Iverson B, Georgiou G. 2000. Quantitative analysis of the effect of the mutation frequency on the affinity maturation of antibodies. Proc Natl Acad Sci USA In press). DNA shuff...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Atomic weightaaaaaaaaaa
Dissociation constantaaaaaaaaaa
Dissociation constantaaaaaaaaaa
Login to View More

Abstract

A composition and method for treating a host having or at risk of infection by Bacillus anthracis using an affinity matured antibody or portion thereof derived from a monoclonal antibody.

Description

[0001]This application is a conversion from and claims priority of U.S. Provisional Application No. 60 / 332,849, filed on Nov. 5, 2001.[0002]The United States Government may own certain rights in this invention under US Army, UT Austin Acct. No.: 26-0454-85 and DOD Grant No.: DAA21-93C-0101.BACKGROUND OF THE INVENTIONTechnical Field of the Invention[0003]The present invention relates generally to the field of antibody engineering and in particular to a neutralizing antibody construct with therapeutic utility in early and advanced stages of therapy.[0004]Without limiting the scope of the invention, its background is described in connection with the treatment of Bacillus anthracis infection, one of the first biological warfare agents to be developed and is now perceived as a major threat in the United States, as an example.[0005]Heretofore, in this field, research on the spore forming bacterium Bacillus anthracis has been limited due to its rare occurrence in humans. Infections due to ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07K16/40A61K39/07G01N33/53A61K39/395A61P31/04C07K16/12C07K16/18C12N15/09C12P21/08C12R1/01G01N33/569
CPCA61K2039/505C07K16/1278C07K2317/55C07K2317/622C07K2317/626Y10S530/865Y10S530/864Y10S530/866Y10S530/809Y10S530/867A61P31/04
Inventor GEORGIOU, GEORGEIVERSON, BRENT L.MAYNARD, JENNIFER A.
Owner BOARD OF RGT THE UNIV OF TEXAS SYST
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com